Short Interest Don’t Lie: What Next for Achillion Pharmaceuticals Incorporated (NASDAQ:ACHN) Stock After Decrease in Shorted Shares?

November 23, 2016 - By Nellie Frank   ·   0 Comments

Short Interest Don't Lie: What Next for Achillion Pharmaceuticals Incorporated (NASDAQ:ACHN) Stock After Decrease in Shorted Shares?

The stock of Achillion Pharmaceuticals Incorporated (NASDAQ:ACHN) registered a decrease of 9.51% in short interest. ACHN’s total short interest was 11.51M shares in November as published by FINRA. Its down 9.51% from 12.72 million shares, reported previously. With 967,700 shares average volume, it will take short sellers 12 days to cover their ACHN’s short positions. The short interest to Achillion Pharmaceuticals Incorporated’s float is 12.19%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 53.38% since April 21, 2016 and is downtrending. It has underperformed by 58.71% the S&P500.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $536.37 million. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. It currently has negative earnings. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Insitutional Activity: The institutional sentiment increased to 1.52 in Q2 2016. Its up 0.52, from 1 in 2016Q1. The ratio improved, as 21 funds sold all Achillion Pharmaceuticals, Inc. shares owned while 39 reduced positions. 12 funds bought stakes while 48 increased positions. They now own 107.31 million shares or 4.98% less from 112.94 million shares in 2016Q1.
Schwab Charles Investment Management, a California-based fund reported 419,370 shares. Qs Investors Ltd Company holds 0.02% or 277,552 shares in its portfolio. Swiss Financial Bank last reported 189,100 shares in the company. Millennium Ltd Liability Corp owns 3.23 million shares or 0.06% of their US portfolio. Geode Mgmt Lc owns 880,254 shares or 0% of their US portfolio. Moreover, Arrowpoint Asset Mngmt Llc has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 29,194 shares. Goldman Sachs Gru Inc holds 0.01% or 3.98M shares in its portfolio. Teachers holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 187,704 shares. Amalgamated Savings Bank owns 12,379 shares or 0.01% of their US portfolio. The New York-based D E Shaw Com Incorporated has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Parametric Portfolio Associates Ltd Company has 32,787 shares for 0% of their US portfolio. Vanguard Gp Inc reported 8.45M shares or 0% of all its holdings. Ubs Asset Management Americas accumulated 0% or 66,998 shares. The Massachusetts-based Wellington Management Gru Llp has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Globeflex Cap L P has invested 0.19% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Out of 9 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. Achillion Pharma has been the topic of 15 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Chardan Capital Markets upgraded it to “Neutral” rating and $5 target price in Friday, November 4 report. The rating was downgraded by Leerink Swann on Friday, January 29 to “Market Perform”. The firm has “Outperform” rating given on Thursday, September 15 by FBR Capital. The firm earned “Market Outperform” rating on Thursday, July 7 by JMP Securities. Wedbush initiated the stock with “Outperform” rating in Friday, September 23 report. Chardan Capital Markets initiated Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Thursday, July 14 with “Sell” rating. The stock has “Sell” rating given by Chardan Capital Markets on Friday, September 23. The rating was maintained by Maxim Group with “Buy” on Thursday, February 25. Jefferies initiated the shares of ACHN in a report on Wednesday, September 9 with “Hold” rating. The firm has “Outperform” rating given on Friday, February 26 by Robert W. Baird.

ACHN Company Profile

Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Firm has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>